Literature DB >> 22930612

Sentinel lymph node biopsy in breast cancer: the node to recovery.

Amit Goyal1.   

Abstract

The widespread adoption of sentinel lymph node biopsy to stage the axilla has led to decrease in arm and shoulder morbidity. Sentinel lymph node biopsy is suitable for patients with clinically/radiologically node negative invasive breast cancer and selected patients with DCIS (those with clinical/radiological mass or extensive lesions requiring mastectomy). The combined isotope-blue dye injection technique gives the best results. We inject the isotope intra-dermally preoperatively and blue dye dye subdermally after anesthetic induction into the tumour quadrant peri-areolar tissue. Lymphoscintiscan is not necessary but is useful during the learning phase. Sentinel node biopsy can be performed through a small transverse or vertical axillary incision (∼3 cm) appropriately placed to allow axillary lymph node clearance if needed.

Entities:  

Keywords:  Blue dye; Breast cancer; Radioisotope; Sentinel lymph node biopsy

Year:  2010        PMID: 22930612      PMCID: PMC3420994          DOI: 10.1007/s13193-010-0005-y

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  23 in total

1.  A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer.

Authors:  A M Derossis; J Fey; H Yeung; S D Yeh; A S Heerdt; J Petrek; K J VanZee; L L Montgomery; P I Borgen; H S Cody
Journal:  J Am Coll Surg       Date:  2001-11       Impact factor: 6.113

2.  Highest isotope count does not predict sentinel node positivity in all breast cancer patients.

Authors:  R C Martin; J Fey; H Yeung; P I Borgen; H S Cody
Journal:  Ann Surg Oncol       Date:  2001-08       Impact factor: 5.344

3.  Randomized clinical trial comparing blue dye with combined dye and isotope for sentinel lymph node biopsy in breast cancer.

Authors:  W K Hung; C M Chan; M Ying; S F Chong; K L Mak; A W C Yip
Journal:  Br J Surg       Date:  2005-12       Impact factor: 6.939

4.  Subareolar versus peritumoral injection for location of the sentinel lymph node.

Authors:  V S Klimberg; I T Rubio; R Henry; C Cowan; M Colvert; S Korourian
Journal:  Ann Surg       Date:  1999-06       Impact factor: 12.969

5.  Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study.

Authors:  K M McMasters; S L Wong; R C Martin; C Chao; T M Tuttle; R D Noyes; D J Carlson; A L Laidley; T Q McGlothin; P B Ley; C M Brown; R L Glaser; R E Pennington; P S Turk; D Simpson; P B Cerrito; M J Edwards
Journal:  Ann Surg       Date:  2001-05       Impact factor: 12.969

6.  Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer.

Authors:  Stephen P Povoski; Johannes O Olsen; Donn C Young; Johannah Clarke; William E Burak; Michael J Walker; William E Carson; Lisa D Yee; Doreen M Agnese; Rodney V Pozderac; Nathan C Hall; William B Farrar
Journal:  Ann Surg Oncol       Date:  2006-09-07       Impact factor: 5.344

7.  Lymphatic mapping and sentinel node biopsy in the patient with breast cancer.

Authors:  J J Albertini; G H Lyman; C Cox; T Yeatman; L Balducci; N Ku; S Shivers; C Berman; K Wells; D Rapaport; A Shons; J Horton; H Greenberg; S Nicosia; R Clark; A Cantor; D S Reintgen
Journal:  JAMA       Date:  1996-12-11       Impact factor: 56.272

8.  Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial.

Authors:  Grantley Gill
Journal:  Ann Surg Oncol       Date:  2008-12-03       Impact factor: 5.344

9.  Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial.

Authors:  Jean-François Rodier; Michel Velten; Marc Wilt; Pierre Martel; Gwanaël Ferron; Véronique Vaini-Elies; Hervé Mignotte; Alain Brémond; Jean-Marc Classe; François Dravet; Thierry Routiot; Christine Tunon de Lara; Antoine Avril; Gérard Lorimier; Eric Fondrinier; Gilles Houvenaeghel; Sandrine Avigdor
Journal:  J Clin Oncol       Date:  2007-05-07       Impact factor: 44.544

10.  Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer--results of the ALMANAC validation phase.

Authors:  Amit Goyal; Robert G Newcombe; Alok Chhabra; Robert E Mansel
Journal:  Breast Cancer Res Treat       Date:  2006-03-16       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.